Last checked at 28 Oct 2021 15:40
genedrive plc
("genedrive" or the "Company")
Notice of Results
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that it will release its financial results for the year ended 30 June 2021 on Tuesday 9 November 2021.
genedrive will be hosting a live online presentation on Thursday, 11 November at 14:00, delivered by David Budd, CEO.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet genedrive plc via:
https://www.investormeetcompany.com/genedrive-plc/register-investor
Investors who already follow genedrive plc on the Investor Meet Company platform will automatically be invited.
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
David Budd: CEO / Matthew Fowler: CFO | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 |
James Steel | |
finnCap (Joint Broker) | +44 (0)20 7220 0500 |
Geoff Nash / Kate Bannatyne / Alice Lane | |
Walbrook PR Ltd (Media & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 |
About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, Antibiotic Induced Hearing Loss and certain military biological targets. The Company released a high throughput SARS-CoV-2 assay in 2020 and has a point of care version of the SARS-Cov-2 test due on market during 2021.